Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh

201139 citationsJournal Articlehybrid Open Access

Authors

S Khatun · Bangabandhu Sheikh Mujib Medical University

SM Hussain · Bangabandhu Sheikh Mujib Medical University

S Chowdhury

Jannatul Ferdous · Bangabandhu Sheikh Mujib Medical University

F Hossain · Bangabandhu Sheikh Mujib Medical University

Sharmin Begum · Bangabandhu Sheikh Mujib Medical University

Munira Jahan · Bangabandhu Sheikh Mujib Medical University

Abstract

The human papillomavirus-16/18 AS04-adjuvanted vaccine was generally well tolerated and highly immunogenic when administered to young adolescent females and could be a promising tool for the prevention and control of cervical cancer in Bangladesh.

Topics & Keywords

Cervical Cancer and HPV Research Hepatitis B Virus Studies Genital Health and Disease

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Japanese Journal of Clinical Oncology

Volume 42, Issue 1, pp. 36-41

DOI: 10.1093/jjco/hyr173

Field-Weighted Citation Impact: 1.76